Eric Hesse
YOU?
Author Swipe
View article: New Insights Into Diffuse Sclerosing Osteomyelitis: Is There a Role of <scp>ANA</scp> and Vitamin <scp>B6</scp>?
New Insights Into Diffuse Sclerosing Osteomyelitis: Is There a Role of <span>ANA</span> and Vitamin <span>B6</span>? Open
Object Diffuse sclerosing osteomyelitis is a poorly understood chronic disease, which appears predominantly in the mandible. Female patients are more often affected than men. DSO is an ultra‐rare disease and incidence is unknown; diagnosis…
View article: Muscle impairments in osteogenesis imperfecta: a narrative review
Muscle impairments in osteogenesis imperfecta: a narrative review Open
The aim of this review is to provide an overview of the available evidence on the effects of OI on skeletal muscle. This encompasses multiple components of muscle function, underlying biological and environmental factors, clinical and func…
View article: Paradoxical combination of osteosclerosis and osteopenia in an adult woman with biallelic <i>TNFRSF11A</i> loss-of-function variants escaping nonsense-mediated decay
Paradoxical combination of osteosclerosis and osteopenia in an adult woman with biallelic <i>TNFRSF11A</i> loss-of-function variants escaping nonsense-mediated decay Open
Osteoclasts are essential for bone resorption, playing a crucial role in skeletal development, homeostasis, and remodeling. Their differentiation depends on the RANK receptor encoded by the TNFRSF11A gene, with defects in this gene linked …
View article: Recommendations for the optimal use of bone forming agents in osteoporosis
Recommendations for the optimal use of bone forming agents in osteoporosis Open
Bone forming agents, also known as anabolic therapies, are essential in managing osteoporosis, particularly for patients at very high-risk of fractures. Identifying candidates who will benefit the most from these treatments is crucial. For…
View article: Elevated levels of Protein S in Multiple Myeloma bone marrow microenvironment regulate tumor progression and bone disease
Elevated levels of Protein S in Multiple Myeloma bone marrow microenvironment regulate tumor progression and bone disease Open
The TAM (TYRO3, AXL, and MERTK) family of receptor tyrosine kinases exhibit cell-transforming capacity promoting tumorigenesis, metastasis and therapy-resistance in various cancer entities. GAS6-MERTK axis represents a target in Multiple M…
View article: Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by activating PAK3 signaling
Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by activating PAK3 signaling Open
Osteoblast adherence to bone surfaces is important for remodeling bone tissue. This study demonstrates that deficiency of TG-interacting factor 1 (Tgif1) in osteoblasts results in altered cell morphology, reduced adherence to collagen type…
View article: TAM receptors control actomyosin dynamics in osteoclasts via RHOA-COFILIN-MYOSIN II signaling
TAM receptors control actomyosin dynamics in osteoclasts via RHOA-COFILIN-MYOSIN II signaling Open
The TAM family of receptor tyrosine kinases were recently identified to regulate bone homeostasis by controlling osteoblasts and bone formation. Despite extensive knowledge of TAM receptor function in the mononuclear phagocyte system, the …
View article: Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by activating PAK3 signaling
Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by activating PAK3 signaling Open
Summary Osteoblast adherence to bone surfaces is important for remodeling of the bone tissue. This study demonstrates that deficiency of TG-interacting factor 1 (Tgif1) in osteoblasts results in altered cell morphology, reduced adherence t…
View article: Author Response: Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by activating PAK3 signaling
Author Response: Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by activating PAK3 signaling Open
Osteoblast adherence to bone surfaces is important for remodeling of the bone tissue. This study demonstrates that deficiency of TG-interacting factor 1 (Tgif1) in osteoblasts results in altered cell morphology, reduced adherence to collag…
View article: Reviewer #1 (Public Review): Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by suppressing PAK3 signaling
Reviewer #1 (Public Review): Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by suppressing PAK3 signaling Open
Osteoblast adherence to bone surfaces is important for remodeling of the bone tissue. This study demonstrates that deficiency of TG-interacting factor 1 (Tgif1) in osteoblasts results in altered cell morphology, reduced adherence to collag…
View article: Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by activating PAK3 signaling
Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by activating PAK3 signaling Open
Osteoblast adherence to bone surfaces is important for remodeling bone tissue. This study demonstrates that deficiency of TG-interacting factor 1 (Tgif1) in osteoblasts results in altered cell morphology, reduced adherence to collagen type…
View article: Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by suppressing PAK3 signaling
Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by suppressing PAK3 signaling Open
Summary Osteoblast adherence to bone surfaces is important for remodeling of the bone tissue. This study demonstrates that deficiency of TG-interacting factor 1 (Tgif1) in osteoblasts results in altered cell morphology, reduced adherence t…
View article: Reviewer #2 (Public Review): Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by suppressing PAK3 signaling
Reviewer #2 (Public Review): Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by suppressing PAK3 signaling Open
Osteoblast adherence to bone surfaces is important for remodeling of the bone tissue. This study demonstrates that deficiency of TG-interacting factor 1 (Tgif1) in osteoblasts results in altered cell morphology, reduced adherence to collag…
View article: Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by activating PAK3 signaling
Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by activating PAK3 signaling Open
Summary Osteoblast adherence to bone surfaces is important for remodeling of the bone tissue. This study demonstrates that deficiency of TG-interacting factor 1 (Tgif1) in osteoblasts results in altered cell morphology, reduced adherence t…
View article: Fibrous Dysplasia of the Jaw: Advances in Imaging and Treatment
Fibrous Dysplasia of the Jaw: Advances in Imaging and Treatment Open
A total of 7% of all benign bone lesions are diagnosed as fibrous dysplasia (FD). The symptoms of FD of the jaw range from asymptomatic to dental anomalies, pain and facial asymmetry. Due to its resemblance to other fibro-osseous bone lesi…
View article: Supplementary Figure S7 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease
Supplementary Figure S7 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease Open
Supplementary Figure S7. miR-135 and miR-203 reduce breast cancer metastasis to lung.
View article: Data from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease
Data from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease Open
Progression of breast cancer to metastatic bone disease is linked to deregulated expression of the transcription factor Runx2. Therefore, our goal was to evaluate the potential for clinical use of Runx2-targeting miRNAs to reduce tumor gro…
View article: Supplementary Figure S5 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease
Supplementary Figure S5 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease Open
Supplementary Figure S5. Expression of exogenous miR-135 and miR-203 in orthotopically transplanted breast cancer.
View article: Supplementary Figure S3 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease
Supplementary Figure S3 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease Open
Supplementary Figure S3. Delivery of miR-135 and miR-203 reduce chemotactic migration of MDA-MB-231 cells.
View article: Supplementary Figure S4 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease
Supplementary Figure S4 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease Open
Supplementary Figure S4. Delivery of miR-135 and miR-203 decrease the expression of CCL-7 and CXCL-12.
View article: Supplementary Figure Legends from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease
Supplementary Figure Legends from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease Open
Supplementary Figure Legends. Legends for Supplementary Figures S1-S7.
View article: Supplementary Figure S2 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease
Supplementary Figure S2 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease Open
Supplementary Figure S2. Runx2 and Runx2-targeting miRNAs are regulated in metastatic breast cancer cells and bone metastases.
View article: Supplementary Figure S1 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease
Supplementary Figure S1 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease Open
Supplementary Figure S1. Runx2 and Smad5 expression in primary breast tumors.
View article: Supplementary Figure S2 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease
Supplementary Figure S2 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease Open
Supplementary Figure S2. Runx2 and Runx2-targeting miRNAs are regulated in metastatic breast cancer cells and bone metastases.
View article: Data from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease
Data from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease Open
Progression of breast cancer to metastatic bone disease is linked to deregulated expression of the transcription factor Runx2. Therefore, our goal was to evaluate the potential for clinical use of Runx2-targeting miRNAs to reduce tumor gro…
View article: Supplementary Figure Legends from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease
Supplementary Figure Legends from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease Open
Supplementary Figure Legends. Legends for Supplementary Figures S1-S7.
View article: Supplementary Figure S7 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease
Supplementary Figure S7 from Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease Open
Supplementary Figure S7. miR-135 and miR-203 reduce breast cancer metastasis to lung.